Laboratory for Molecular Diagnostics
Center for Nephrology and Metabolic Disorders

Apolipoprotein F

The APOF gene encodes apolipoprotein F, a protein formerly known as lipid transfer inhibitor protein (LTIP), is synthesized by the liver and activated in the circulation. It inhibits the CETP and LCAT probably in a way to control the direction of lipid transfer. The activation of apolipoprotein F depends on the composition of LDL particles. While apolipoprotein F deficiency did not significantly alter the lipid profile, overexpression reduces HDL.

Genetests:

Research Method Carrier testing
Turnaround 5 days
Specimen type genomic DNA
Research Method Genomic sequencing of the entire coding region
Turnaround 25 days
Specimen type genomic DNA

Related Diseases:

Apolipoprotein F deficiency
APOF

References:

1.

Lagor WR et al. (2009) Overexpression of apolipoprotein F reduces HDL cholesterol levels in vivo.

[^]
2.

Olofsson SO et al. (1978) Isolation and partial characterization of a new acidic apolipoprotein (apolipoprotein F) from high density lipoproteins of human plasma.

[^]
3.

Lagor WR et al. (2012) The effects of apolipoprotein F deficiency on high density lipoprotein cholesterol metabolism in mice.

[^]
4.

Koren E et al. (1982) Isolation and characterization of simple and complex lipoproteins containing apolipoprotein F from human plasma.

[^]
5.

Day JR et al. (1994) Purification and molecular cloning of human apolipoprotein F.

[^]
6.

Wang X et al. (1999) Molecular cloning and expression of lipid transfer inhibitor protein reveals its identity with apolipoprotein F.

[^]
Update: Sept. 26, 2018